Molecular investigations of protriptyline as a multi-target directed ligand in alzheimer's disease

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Bansode, Sneha B ^a   Jana, Asis K ^a   Batkulwar, Kedar B ^a   Warkad, Shrikant D ^a   Joshi, Rakesh S ^a   Sengupta, Neelanjana ^a   Kulkarni, Mahesh J ^a  

^a NATIONAL CHEMICAL LABORATORY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; BETA SECRETASE; DOXEPIN; MAPROTILINE; NORTRIPTYLINE; PROTRIPTYLINE; ANTIDEPRESSANT AGENT; LIGAND; SECRETASE;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; ATOMIC FORCE MICROSCOPY; COMPUTER MODEL; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; GLYCATION; ISOTHERMAL TITRATION CALORIMETRY; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PHOTOCHEMICAL QUENCHING; PROTEIN AGGREGATION; PROTEIN GLYCOSYLATION; VIRTUAL REALITY; ANIMAL; KINETICS; METABOLISM; TUMOR CELL LINE;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTIDEPRESSIVE AGENTS; CELL LINE, TUMOR; KINETICS; LIGANDS; MICE; MOLECULAR DYNAMICS SIMULATION; PROTRIPTYLINE;

EID: 84924983106     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105196     Document Type: Article

References (56)

1. Roberson E, Mucke L (2006) 100 Years and Counting: Prospects for Defeating Alzheimer's Disease. Science 314: 781-784. (Pubitemid 44706637)
2. Bartus RT, Dean III RL, Beer B, Lippa AS (1982) The Cholinergic Hypothesis of Geriatric Memory Dysfunction. Science 217: 408-414.
3. Alzheimer's Association: FDA-approved treatments for Alzheimers. Available: https://www.alz.org/national/documents/topicsheet-treatments.pdf 2012.
4. Small DH (2005) Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer's disease: do we need new inhibitors? Expert Opin Emerg Drugs 10: 817-825.
5. Terry AV Jr, Buccafusco JJ (2003) The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 306: 821-827.
6. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's dis-ease: progress and problems on the road to therapeutics. Science 297: 353-356. (Pubitemid 34790756)
7. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol 8: 101-112. (Pubitemid 46432529)
8. Golde TE (2006) Disease modifying therapy for AD? J Neurochem 99: 689-707.
9. Selkoe DJ (1999) Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399: A23-A31.
10. Citron M (2002) Beta-secretase as a target for the treatment of Alzheimer's disease. J Neurosci Res 70: 373-379.
11. Hussain I (2004) The potential for BACE-1 inhibitors in the treatment of Alzheimer's disease. IDrugs 7: 653-658.
12. Hills ID, Vacca JP (2007) Progress toward a practical BACE-1 inhibitor. Curr Opin Drug Discov Devel 10: 383-91. (Pubitemid 47093121)
13. Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, et al. (1994) Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Nat Acad Sci USA 91: 4766-4770. (Pubitemid 24177730)
14. Li XH, Du LL, Cheng XS, Jiang X, Zhang Y, et al. (2013) Glycation exacerbates the neuronal toxicity of β-amyloid. Cell Death and Disease 4: e673.
15. Anand P, Singh B (2013) A review on cholinesterase inhibitors for Alzheimer's disease. Arch Pharm Res 36: 375-99.
16. Zhang C (2012) Natural compounds that modulate BACE1-processing of amyloid-beta precursor protein in Alzheimer's disease. Discov Med 14: 189-197.
17. Schenk D, Basi GS, Pangalos MN (2012) Treatment strategies targeting amyloid β-protein. Cold Spring Harb Perspect Med 2: a006387.
18. Götz J, Ittner A (2012) Tau-targeted treatment strategies in Alzheimer's disease. Br J Pharmacol 165: 1246-1259.
19. Youdim MB, Buccafusco JJ (2005) Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci 26: 27-35. (Pubitemid 40052707)
20. Zhang HY (2005) One-compound-multiple-targets strategy to combat Alzheimer's disease. FEBS Lett 579: 5260-5264.
21. Cappelli A, Gallelli A, Manini M, Anzini M, Mennuni L, et al. (2005) Further studies on the interaction of the 5-hydroxytryptamine3 (5-HT3) receptor with arylpiperazine ligands. Development of a new 5-HT3 receptor ligand showing potent acetylcholinesterase inhibitor properties. J Med Chem 48: 3564-3575. (Pubitemid 40667524)
22. Lee S, Zheng X, Krishnamoorthy J, Savelieff MG, Park HM, et al. (2014) Rational design of a structural framework with potential use to develop chemical reagents that target and modulate multiple facets of Alzheimer's disease. J Am Chem Soc 136(1): 299-310.
23. Corbett A, Pickett J, Burns A, Corcoran J, Dunnett SB, et al. (2012) Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov 11: 833-846.
24. Kitchen DB, Decornez H, Furr JR, Bajorath J (2004) Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 3: 935-949. (Pubitemid 39529931)
25. Kellenberger E, Rodrigo J, Muller P, Rognan D (2004) Comparative evaluation of eight docking tools for docking and virtual screening accuracy. Proteins 57: 225-242. (Pubitemid 39223729)
26. Campoy AV, Freire E (2005) ITC in the post-genomic era...? Priceless. Biophys Chem 115: 115-124. (Pubitemid 40327045)
27. Shoemaker BA, Panchenko AR (2007) Deciphering Protein-Protein Interactions. Part I. Experimental Techniques and Databases. PLoS Comput Biol 3: 337-344.
28. Tai K, Shen T, Henchman RH, Bourne Y, Marchot P, et al. (2002) Mechanism of Acetylcholinesterase Inhibition by Fasciculin: A 5-ns Molecular Dynamics Simulation. J Am Chem Soc 124: 6153-6161. (Pubitemid 34552859)
29. Jana AK, Sengupta N (2012) Adsorption mechanism and collapse propensities of the full-length, monomeric Aβ (1-42) on the surface of a single-walled carbon nanotube: a molecular dynamics simulation study. Biophys J 102: 1889-1896.
30. Santini S, Wei G, Mousseau N, Derreumaux P (2004) Pathway Complexity of Alzheimer's β-Amyloid Aβ16-22 Peptide Assembly. Structure 12: 1245-1255. (Pubitemid 38900767)
31. Balbach JJ, Ishii Y, Antzutkin ON, Leapman RD, Rizzo NW, et al. (2000) Amyloid Fibril Formation by Aβ16-22, a Seven-Residue Fragment of the Alzheimer's β-Amyloid Peptide, and Structural Characterization by Solid State NMR. Biochemistry 39: 1374-1375.
32. Bernstein SL, Wyttenbach T, Baumketner A, Shea JE, Bitan G, et al. (2005) Amyloid beta-protein: monomer structure and early aggregation states of Abeta42 and its Pro19 alloform. J Am Chem Soc 127(7): 2075-2084. (Pubitemid 40270509)
33. Tjernberg LO, Näslund J, Lindqvist F, Johansson J, Karlström AR, et al. (1996) Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J Biol Chem 271: 8545-8548. (Pubitemid 26123269)
34. Chimon S, Shaibat MA, Jones CR, Calero DC, Aizezi B, et al. (2007) Evidence of fibril-like β-sheet structures in a neurotoxic amyloid intermediate of Alzheimer's β-amyloid. Nat Struct Mol Biol 14: 1157-1164. (Pubitemid 350223342)
35. Levine H (1993) Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: Detection of amyloid aggregation in solution. Protein Sci 2: 404-410.
36. Lee C, Ham S (2011) Characterizing amyloid-beta protein misfolding from molecular dynamics simulations with explicit water. J Comput Chem 32: 349-355.
37. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, et al. (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 7: 63-80. (Pubitemid 40387185)
38. Li J, Liu D, Sun L, Lu Y, Zhang Z (2012) Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective. J Neurol Sci 317: 1-5.
39. Gulyaeva N, Zaslavsky A, Lechner P, Chlenov M, McConnell O, et al. (2003) Relative hydrophobicity and lipophilicity of drugs measured by aqueous two-phase partitioning, octanol-buffer partitioning and HPLC. A simple model for predicting blood-brain distribution. Eur J Med Chem 38: 391-396. (Pubitemid 36577189)
40. Aboukhatwa M, Dosanjh L, Luo Y (2010) Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease. Mol Neurodegener 5: 10.
41. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, et al. (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 16: 2785-2791.
42. Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31: 455-461.
43. Saeed AI, Bhagabati NK, Braisted JC, Liang W, Sharov V, et al. (2006) TM4 Microarray Software Suite. Methods Enzymol 411: 134-193.
44. Ellman GL, Courtney D, Andres V, Featherston RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7: 88-95.
45. Copeland RA, Lombardo D, Giannaras J, Decicco CP (1995) Estimating ki values for tight binding inhibitors from dose-response plots. Bioorganic & Medicinal Chemistry Letters 5: 1947-1952.
46. Tamhane VA, Chougule NP, Giri AP, Dixit AR, Sainani MN, et al. (2005) In vivo and in vitro effect of Capsicum annum proteinase inhibitors on Helicoverpa armigera guts proteinases. Biochim Biophys Acta 1722: 156-167. (Pubitemid 40299006)
47. Kale L, Skeel R, Bhandarkar M, Brunner R, Gursoy A, et al. (1999) NAMD2: Greater Scalability for Parallel Molecular Dynamics. Comput Phys 151: 283-312.
48. MacKerell AD Jr, Bashford D, Bellott M, Dunbrack RL, Evanseck JD, et al. (1998) All-Atom Empirical Potential for Molecular Modeling and Dynamics Studies of Proteins. J Phys Chem B 102: 3586-3616. (Pubitemid 128576688)
49. Mackerell AD Jr, Feig M, Brooks CL 3rd (2004) Extending the treatment of backbone energetics in protein force fields: limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations. J Comput Chem 25: 1400-1415.
50. Zoete V, Cuendet MA, Grosdidier A, Michielin O (2011) SwissParam: a fast force field generation tool for small organic molecules. J Comput Chem 32: 2359-2368.
51. Hill EH, Stratton K, Whitten DG, Evans DG (2012) Molecular dynamics simulation study of the interaction of cationic biocides with lipid bilayers: aggregation effects and bilayer damage. Langmuir 28: 14849-14854.
52. Mabanglo MF, Serohijos AW, Poulter CD (2012) The Streptomyces-produced antibiotic fosfomycin is a promiscuous substrate for Archaeal isopentenyl phosphate kinase. Biochemistry 51: 917-925.
53. Caulfield T, Medina-Franco JL (2011) Molecular dynamics simulations of human DNA methyltransferase 3B with selective inhibitor nanaomycin A. J Struct Biol 176: 185-191.
54. Ryckaert JP, Ciccotti G, Berendsen HJC (1977) Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 23: 327-341.
55. Feller SE, Zhang Y, Pastor RW, Brooks BR (1995) Constant pressure molecular dynamics simulation: The Langevin piston method. J Chem Phys 103: 4613-4621.
56. Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, et al. (1995) A smooth particle mesh Ewald method. J Chem Phys 103: 8577-8593.